Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoBio Announces Closing of $22 Million Series B Financing Round

Abstract:
Funds Will Support Clinical Trials and Ongoing Operations Through Early 2011

NanoBio Announces Closing of $22 Million Series B Financing Round

Ann Arbor, MI | Posted on July 8th, 2009

NanoBio Corp., a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines, announced today that it has closed a $22 million Series B financing round after recently securing an additional $10 million investment from NanoBio's majority shareholder Perseus, L.L.C., based in New York, NY, and Venture Investors of Madison, WI and Ann Arbor, MI. The $10 million is in addition to the $12 million Series B funding announced in February 2009. To date, NanoBio has received more than $90 million in equity and grant funding to support the development of the company's anti-infective products and nanoemulsion-based vaccines.

"This investment round secures our ability to independently fund the next two years of our operations," commented James R. Baker, Jr., MD, NanoBio's CEO and founder. "Our investors see the tremendous value of our platform technology from both a medical and commercial perspective. There is a clear need for novel topical anti-infective therapies and new vaccine-adjuvant approaches that offer safety, ease of use, and enhanced efficacy."

The funding will support the advancement of numerous clinical and preclinical programs, including the development of products for herpes labialis, onychomycosis, acne, and cystic fibrosis as well as intranasal vaccines for seasonal influenza and other diseases. The company will begin a Phase 1 clinical study in acne this summer and is planning to initiate a phase III study in herpes labialis. In addition, the company is currently conducting a Phase 1 clinical study in NB-1008, a seasonal influenza vaccine administered via a nasal dropper.

NB-1008 uses a novel nanoemulsion-based adjuvant to achieve a robust immune response using only a small fraction of the antigen required by currently available injectable vaccines. In numerous animal studies, NB-1008 has demonstrated robust mucosal, systemic and cellular immunity without inflammation or safety concerns.

"NanoBio is a compelling investment choice, offering a strong scientific basis supported by promising ongoing trial results," commented George Arida, managing director for Venture Investors' healthcare practice. "At a time when investors have a multitude of good companies seeking financing, we are selectively backing those with strong management teams and novel technology that have the potential to create significant change in the healthcare landscape."

####

About NanoBio Corp.
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead dermatology and anti-infective product candidates include treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, molluscum contagiosum, and cystic fibrosis. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

For more information, please click here

Contacts:
2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone: 734.302.4000
Fax: 734.302.9150

V.P. Business Development
John Coffey (Ext. 107)

Copyright © NanoBio Corp.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iranian Researchers Synthesize Stable Ceramic Nanopowders at Room Temperature September 20th, 2014

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014

Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014

Investments/IPO's/Splits

PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014

Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 August 12th, 2014

Nanomedicine

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

The Pocket Project will develop a low-cost and accurate point-of-care test to diagnose Tuberculosis: ICN2 holds a follow-up meeting of the Project on September 18th - 19th September 18th, 2014

New non-invasive technique could revolutionize the imaging of metastatic cancer September 17th, 2014

Recruiting bacteria to be technology innovation partners: September 17th, 2014

Announcements

Iranian Scientists Separate Zinc Ion at Low Concentrations September 20th, 2014

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014

Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014

Nanobiotechnology

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

CiQUS researchers design an artificial nose to detect DNA differentiation with single nucleotide resolution September 18th, 2014

Biosensors Get a Boost from Graphene Partnership: $5 Million Investment Supports Dozens of Jobs and Development of 300mm Fabrication Process and Wafer Transfer Facility September 18th, 2014

Recruiting bacteria to be technology innovation partners: September 17th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE